longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Aimei Health Tech

AFJK

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Weekly Recap | Zai Lab -2.8%, most brokers rate it buy

    Weekly Review·Sep 26 at 07:23 AM
    - Zai Lab shares fell 2.8% to close at 24.98 USD this week, underperforming the S&P 500 index by 4.01 percentage points amid shrinking trading volume and no major catalysts. - Among 12 covering institutions, 9 rated the stock as a buy and 2 as overweight, resulting in a strong buy consensus with an average target price of 33.14 USD. - Next week's focus will center on US macroeconomic data impacting the biotechnology sector's risk appetite, while Zai Lab has no major events or earnings reports scheduled.
    ZLAB+1.66%
  • Weekly Recap | Sarepta Therap -7.16%, consensus target above spot

    Weekly Review·Sep 26 at 07:08 AM
    SRPT-0.78%SRPU0.00%
  • Weekly Recap | Novavax +5.14%, consensus target above spot

    Weekly Review·Sep 26 at 06:55 AM
    NVAX+0.47%
  • Weekly Recap | Legend Biotech +8.52%, most brokers rate it buy

    Weekly Review·Sep 26 at 06:37 AM
    LEGN+4.49%
  • Weekly Recap | IOVA.US +7.32%, most brokers rate it buy

    Weekly Review·Sep 26 at 06:33 AM
    IOVA+0.87%
  • Weekly Recap | GENB.US -11.61%, consensus target above spot

    Weekly Review·Sep 26 at 06:23 AM
    GENB-0.94%
  • Weekly Recap | Cypherpunk Tech +14.44%, a sharp V-shaped recovery

    Weekly Review·Sep 26 at 06:13 AM
    CYPH+6.50%